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Abstract
Background: We explore vaccination strategies against pandemic influenza in Mexico using an age-structured transmission
model calibrated against local epidemiological data from the Spring 2009 A(H1N1) pandemic.
Methods and Findings: In the context of limited vaccine supplies, we evaluate age-targeted allocation strategies that either
prioritize youngest children and persons over 65 years of age, as for seasonal influenza, or adaptively prioritize age groups
based on the age patterns of hospitalization and death monitored in real-time during the early stages of the pandemic.
Overall the adaptive vaccination strategy outperformed the seasonal influenza vaccination allocation strategy for a wide
range of disease and vaccine coverage parameters.
Conclusions: This modeling approach could inform policies for Mexico and other countries with similar demographic
features and vaccine resources issues, with regard to the mitigation of the S-OIV pandemic. We also discuss logistical issues
associated with the implementation of adaptive vaccination strategies in the context of past and future influenza
pandemics.
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Introduction
Although countries have developed influenza pandemic pre-
paredness plans, uncertainties remain in terms of the virulence and
transmissibility of pandemic strains as well as population immunity
profiles. In particular, there has been heterogeneity in the past
three influenza pandemics of the 20th Century [1,2] with regard to
transmissibility, ranging from an average of 1.5 to 5.4 secondary
cases per primary case in the community; [3,4,5,6,7]; case fatality
rate, range, 0.1%–4% [3,8] ; and age-specific mortality rates [3,9].
While differences in transmissibility and case fatality rate remain
poorly understood, mortality age patterns could be explained in
part by the history of previously circulating influenza viruses, with
early-life exposure to related viruses reducing risk for severe
pandemic outcomes [10,11]. Moreover, recent studies have
evidenced important geographical variations in pandemic mor-
bidity and mortality burden [2,7,12,13,14,15], as well as variations
in severity of successive pandemic waves. Pandemic preparedness
plans have not adequately incorporated such uncertainties, which
are difficult to resolve prior to pandemic onset but can be deduced
once a novel pandemic virus is identified.
Given the variety of possible pandemic scenarios, specific
information on virus sub-type and age patterns of incidence and
mortality during the early phase of a pandemic could help
prioritize allocation of limited resources and optimize reductions
in disease burden. Containment [16,17,18,19] and control
strategies for influenza pandemics have been explored by
simulations and applied to several countries or regions, including
Southeast Asia [16,18], US [20,21,22,23], UK [23], and Nether-
lands [22,23,24]. None of these simulations featured adaptive
intervention strategies that integrate epidemiological data collected
in real time during the first weeks of the outbreak. The recent
emergence of a novel swine-origin influenza A/H1N1 virus (S-
OIV) in Mexico [25] and rapid global spread [26] provides an
opportunity for modeling in a real-time pandemic situation and
may provide guidance for public health officials in many countries.
A(H1N1) S-OIV pandemic influenza virus continues to spread
throughout the Northern and Southern hemispheres. While there
are plans to formulate a vaccine against the new A(H1N1) strain,
current licensed manufacturing processes are insufficient to protect
the majority of the six plus billion people who may be potentially
exposed during the first pandemic wave. Through a review of the
epidemiology thus far and principles of past pandemics, vaccine
efficacy and transmissibility factors within and between age
groups, we provide an optimization strategy to minimize severe
morbidity and mortality burden from this virus. Specifically, we
evaluate the effectiveness of various age-targeted vaccination
strategies against pandemic influenza when vaccine supplies are
limited. We propose novel ‘adaptive’ real-time vaccination
strategies that may guide vaccine allocation based on the age
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patterns of morbidity and mortality of an on-going outbreak, and
compare their effectiveness with that of strategies targeted towards
traditional influenza high risk age groups, i.e., young children and
seniors. We calibrate our models against local demographic and
epidemiological data from the 2009 outbreak of S-OIV in Mexico
in an emerging scenario and explore a moderate pandemic
scenario illustrating the epidemiology of the 1957- or 1968
pandemics and a severe pandemic scenario illustrating the unusual
concentration of hospitalizations and deaths in young adults
observed during the 1918-pandemic.
Materials and Methods
To compare the effectiveness of various vaccination strategies
against pandemic influenza in Mexico, we used an age-structured
influenza transmission model that accounts for age-specific risk of
illness, hospitalization, and death and simulated a variety of
epidemiological and vaccination scenarios encompassing the
diversity of observed disease patterns from previous pandemics.
Incidence rates of clinical cases, hospitalizations and deaths in the
absence of vaccination were estimated based on the outbreak of S-
OIV in Mexico. In this simulation approach, we assume limited
vaccine supplies and age variation in vaccine efficacy. Below we
describe the structure of the transmission model, discuss the
pandemic scenarios considered, and detail the different vaccina-
tion strategies evaluated.
Transmission Model
Figure 1 provides a schematic of the transmission model that
includes 6 age groups (0–5 y, 6–12 y, 13–19 y, 20–39 y, 40–59 y,
.= 60 y). We integrate the age structure of the Mexican
population to the influenza transmission model, based on data
from the 2000 Census (Figure S1). Further, each age group
(indexed by i) is classified into 9 epidemiological states given by:
susceptible (Si), effectively vaccinated but not yet protected (Vi),
ineffectively vaccinated (Ui), protected by vaccination (Pi), latent
(Ei), symptomatic and infectious in the community (Ii), hospitalized
(Hi), recovered (Ri), and dead (Di). Susceptible individuals in age
group i are exposed to the influenza virus at the force of infection
li~
P6
j~1 bij
IjzHj
N tð Þ where bij is the transmission rate between age
groups i and j and the total population size is given by
N tð Þ~
X6
k~1
Sk tð ÞzVk tð ÞzUk tð ÞzPk tð Þ
zEk tð ÞzIk tð ÞzHk tð ÞzRk tð Þ:
The transmission rates bij are given by qcij where q is the
transmission probability per contact (fraction of contacts that leads to
infection), which is assumed to be constant across age groups as in
previous studies [24], and cij are the age-specific contact rates which are
modeled based on a study describing self-reported age-specific contact
rates for the spread of respiratory infections [27] (Table S1). Although
information on contact rates is limited [28], transmission models
calibrated with frequency dependent contact rates derived from social
survey have been shown to provide better approximations to attack
rates of the 1957 influenza pandemic than other mixing assump-
tions[27]. The contact rate matrix is highly assortative with higher
mixing rates within each age group than between age groups and
follows a similar pattern to that of several European countries [29].
Contact rates among 6–12 year olds are the highest and rates among
seniors (.= 60 y) are the lowest. Latent individuals Ei progress to the
infectious class Ii at the rate k (1/k is the mean latent period). Infectious
individuals are hospitalized at the age-specific mean rates ai and
recover at the mean rate c1. Hospitalized individuals either recover at
the constant rate c2 or die from influenza at the age-specific rate di.
While the age-specific hospitalization rates are adjusted using estimates
of the probability of hospitalization given clinical illness by age group,
the recovery rate c2 is assumed to be constant across age groups for
simplicity. Recovered individuals are assumed to remain protected for
the duration of the epidemic. Infected individuals die with an age-
specific mortality rates as described below. Vaccination is administered
to susceptible individuals t* days after the epidemic onset with a
vaccination rate n(t). That is, n(t) = 0 whenever t , t*. Age-specific
vaccine efficacy is denoted by ei. Successfully vaccinated individuals
(Vi) progress to the protected class (Pi) at the rate g (mean of 10 days)
while ineffectively vaccinated individuals (Ui) remain susceptible to
infection. Vaccinated but not yet protected individuals (Vi) may still be
infected with influenza at the age-dependent force of infection li as
described above. The population is assumed to be completely
susceptible at the beginning of the epidemic. The system of differential
equations that describes our influenza transmission model is given by
d Si
d t
~{n tð ÞSi{li Si
d Vi
d t
~ei n tð ÞSi{gVi{li Vi
dUi
d t
~ 1{eið Þn tð ÞSi{li Ui
d Pi
d t
~gVi
dEi
d t
~li SizVizUið Þ{kEi (1)
d Ii
d t
~kEi{ aizc1ð ÞIi
dHi
d t
~aiIi{ c2zdið ÞHi
dRi
d t
~c1Iizc2Hi
dDi
d t
~di Hi
for i~1,    6:
The hospitalization and mortality rates are given by ai = (pHi/
(1 2 pHi ))c1 and di = (CFPi/(12CFPi)) c2, respectively, where pHi
Figure 1. Flow chart of the stage progression of the individuals
among the different epidemiological classes.
doi:10.1371/journal.pone.0008164.g001
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and CFPi denote the probability of hospitalization given clinical
illness and the probability of death following hospitalization for
age group i (Figures S2, S3). Numerous simulations of the model
were conducted by solving the system of ordinary differential
equations using Matlab (The Mathworks, Inc) with initially 5
infectious teenagers (13–19) following the different pandemic
scenarios.
Model Calibration and Reproduction Number Estimates
The basic reproduction number R0, the average number of
secondary cases generated by a primary infectious case during the
initial epidemic period [30,31], quantifies the transmissibility of a
pathogen in naı¨ve populations, while the reproduction number, R,
estimates a similar quantity in partially-naı¨ve populations. These
estimates can help determine the intensity of interventions necessary
for epidemic control. If the average number of secondary infections
is reduced then transmission slows down (transmission is interrupted
if R,1), so that there is less pressure on health care systems and
potentially increased time to prepare additional vaccines. We derive
an expression of the reproduction number from our mathematical
model using standard methods [31] and calibrate our model against
published estimates of the basic reproduction number for this
influenza pandemic in Mexico by adjusting the probability of
transmission given contact (q) (File S1).
Adaptive and Seasonal Vaccination Strategies
Vaccination strategies considered in this study are implemented
after the onset of an influenza pandemic outbreak. We considered
2 strategies, depending on the age targets for vaccination: 1. a
‘seasonal-like influenza vaccination strategy’ targeting the same
high-risk groups as for seasonal vaccination, young children (0–5 y)
and seniors (.= 60 y) 2. an ‘adaptive’ strategy, where vaccine is
allocated on the basis of age-specific hospitalization and mortality
rates reported in real-time during the early pandemic phase.
Vaccine doses are allocated to age groups proportionally to their
corresponding hospitalization or mortality rates. Benefits are
potentially optimized if early reports of age-specific hospitalization
and death are indicative of those at risk throughout all phases of a
pandemic.
We assume that timing of vaccine delivery follows an
exponential distribution with an average of 5 days after the
vaccination campaign is initiated. Vaccine efficacy is assumed to
be 77.5% (range between 75% and 80%) for individuals ,65 y
and 35% (range between 17% and 53%) for seniors over 65 years,
based on reviews of influenza vaccine immunogenicity [32,33,34].
Vaccinated individuals are assumed to develop protection 10 or 30
days after immunization on average depending on the require-
ments of one or two doses of a novel vaccine. Because vaccine is
likely in limited supply during the earliest phase of a pandemic, the
vaccination coverage with the full course of 1–2 doses is assumed
to be relatively low (5%–20%). Our upper bound for vaccination
coverage is consistent with the immunization of about one fifth of
the US population in 1976 against a swine influenza virus [35].
We assume that the same vaccination strategy will be applied
throughout the outbreak or until vaccines resources are depleted.
Pandemics Scenarios
Model parameters describing the epidemiology of pandemic
influenza are given in Table 1. We considered 3 pandemic
scenarios, representing the epidemiology of past and current
pandemics, as explained below.
a) 2009 H1N1 pandemic scenario. To model an
epidemiological pandemic scenario reminiscent of the H1N1
outbreak in Mexico in Spring 2009, we used age-specific
epidemiological data reported to the Mexican National
Epidemiological Surveillance System during this outbreak [36].
Age-specific hospitalization and case fatality rates for hospitalized
cases (age groups 0–4 y, 5–59 y, .= 60 y) were estimated from
cumulative morbidity and mortality data reported on two
epidemiologically-relevant dates of the outbreak: (i) on April 17,
25 days into the outbreaks (March 24 -April 17, 2009), when the
Ministry of Health requested that medical institutions intensify
notification and (ii) on Apr 29, 2009, 37 days into the outbreak,
when selective reporting of pneumonia requiring hospitalization
ceased [25] (Figure 2). We varied the mean reproduction number
within its estimated range 1.4–1.8 for this outbreak [26] and
vaccination coverage levels of 5–20%.
b) Historical pandemic scenarios. We considered two
more scenarios illustrating the age patterns of hospitalizations and
deaths during a pandemic: (i) a moderate pandemic scenario
illustrating the epidemiology of the 1957- or 1968 pandemics, with
increased severe outcomes in young children and seniors [37] and
(ii) a severe pandemic scenario illustrating the unusual
concentration of hospitalizations and deaths in young adults
observed during the 1918-pandemic [38] (Figure S2).
For the 1957- and 1968-like moderate pandemic scenarios, we
estimated age- specific case fatality rates for hospitalized influenza
cases by combining hospitalization (Figure S4) and mortality data
from the city of Guadalajara, Mexico during the period 2000–
2005 (Ministry of Health, State of Jalisco, Mexico, Figure S5). For
the 1918-like severe pandemic scenario, we used historical data
[38] to estimate case fatality rates, which were highest among
young adults (20–39 year-old, Figure S3). The case fatality rate is
likely overestimated for this scenario due to secular improvements
in health care since the 1918 pandemic; however we consider this
simulation a worst-case scenario.
Table 1. Parameter definitions and mean baseline values of influenza epidemiology used in our transmission model.
Parameter Definition Baseline values Source
k Rate of progression from latent to infectious state (1/day) 1/1.9 [19]
ai Diagnostic rate for age group i (1/day) ai~ pHi = 1{pHið Þð Þc1
pHi Fraction of clinical cases that are hospitalized for age group i Figure 2, Figure S2 [36,37,38]
c1 Recovery rate for infectious class (1/day) 1/1.5 (1/4–1) [4]
c2 Recovery rate for hospitalized class (1/day) 1/1.5 (1/4–1) [4]
di Influenza mortality rate for age group i (1/day) di~ CFPi= 1{CFPið Þð Þc2
CFPi Case fatality proportion Figure 2, Figure S3 [36,38]
doi:10.1371/journal.pone.0008164.t001
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Results
2009 A/H1N1 Pandemic Scenario, Based on the
Epidemiology of Influenza in Mexico, Spring 2009
First, we explored a baseline pandemic scenario reminiscent of
the recent Mexican experience with novel S-OIV in the spring of
2009, in the absence of any intervention. Assuming R0 = 1.6, the
peak was reached at about day 120 after the pandemic onset with
a total outbreak duration of about 5 months. Hospitalization rates
varied from about 10% for the 13–19 year-olds to 17% for the
.= 60 year-olds as shown in Figure 3 (top panel). Mortality rates
were estimated at about 2.3-, 1.9- and 0.7-percent for year age
groups 20–39, 13–19, and .= 60 y, respectively.
To define priority groups for the adaptive strategy, we relied on
early estimates of age-specific rates of hospitalization and death,
given epidemiological data reported 25 and 37 days into the
outbreak (Apr 17 and Apr 29; Fig. 2). Assuming R0 = 1.6 (Table 2),
the adaptive strategy yielded reductions of 37% and 42% in the
overall number of hospitalizations and deaths (Figure 3 bottom
panel), respectively, if vaccination started on day 25 of the
outbreak and reached 20% of the population. The benefits of the
adaptive strategy were slightly lower if vaccination started on day
37 of the outbreak and reached 20% of the population. The
adaptive vaccination strategy provided up to 35% additional
reduction in the number of influenza-related deaths and 22%
reduction in hospitalization as compared to the seasonal influenza
strategy (Figures 3), for transmissibility levels of 1.4–1.8 and
vaccination coverage ranging between 5 and 20% (Figure 4).
Given the age patterns of hospitalizations and deaths in the S-OIV
Mexican pandemic scenario, the age group prioritized by the
adaptive strategy was young and middle-aged adults aged 20–59 y.
Historical Pandemic Scenarios
For the severe pandemic scenario illustrating the epidemiology
of the 1918 pandemic with R0 = 1.8 (clinical attack rate across the
population of 39%), the peak was reached at about day 85 after
the pandemic onset with a total outbreak duration of about 4
months. Hospitalization rates varied from about 2,750 per
100,000 individuals for the 40–59 year-olds to 4,250 per
100,000 for the 0–5 year-olds as shown in Figure S6 (top panel).
Mortality rates were estimated at about 500, 420 and 290 deaths
per 100,000 for year age groups 20–39, 0–5, and .= 60 y,
respectively.
The moderate pandemic scenario illustrating the epidemiology
of the 1957- and 1968-pandemics produced similar peak timings
and outbreak duration as the 1918-like scenario, for a given
transmissibility level. As expected, the moderate scenario resulted
in lower hospitalization rates, varying from about 75 per 100,000
individuals for the 6–12 y and 13-19 year-olds to 3,150 per
100,000 for the .= 60 year-olds when R0 = 1.8 (Figure S7 top
panel). Mortality rates were below 9 per 100,000 for all age groups
except for .= 60 year olds with about 475 deaths per 100,000
individuals.
For illustration purposes, we compare the effectiveness of the
‘‘seasonal’’ influenza vaccination strategy targeting young children
and seniors to mitigate disease in severe and moderate pandemic
scenarios (Figures S6 and S7). For the moderate 1957 or 1968-like
pandemic scenario, the ‘‘seasonal’’ vaccination strategy yielded
reductions of 32% and 37% in the overall number of
hospitalizations and deaths, respectively, if vaccination started on
day 10 of the outbreak and reached 20% of the population. The
corresponding reductions for a severe 1918-like pandemic scenario
were 20% and 24%, respectively.
Next, we considered the effectiveness of adaptive strategies
integrating real-time epidemiological data. For the moderate
pandemic scenario, the adaptive strategy yielded reductions of
49% and 43% in the overall number of hospitalizations and
deaths, respectively, if vaccination started on day 10 of the
outbreak and reached 20% of the population. Overall, the
adaptive vaccination strategy outperformed the seasonal strategy
in terms of reducing hospitalizations and deaths for all values of R
and the entire range of vaccination coverage (5–20%). The
adaptive vaccination strategy gave 2–19% additional reduction in
hospitalization and 1–20% additional reduction in deaths,
compared to the seasonal influenza vaccination strategy, when
vaccination was initiated 10 days after pandemic onset. The
superiority of the adaptive strategy held when the vaccination
campaign was initiated 30 days after the epidemic onset (Figure
S8). Overall, the adaptive vaccination strategy substantially
outperformed the seasonal influenza vaccination strategy if
vaccination coverage was relatively high (.10%) and transmissi-
bility remained relatively low (R,3); additional benefits quickly
decreased when R was greater than 3 or vaccination coverage was
less than 10% (Figure S8). In addition, the added benefits of the
adaptive strategy increased when the vaccination campaign started
early. For the moderate pandemic scenario illustrating the
epidemiology of the 1957- and 1968-pandemics, the age groups
prioritized by the adaptive strategy were adults aged 60 and over.
For a severe 1918-like pandemic scenario, the improvements of
the adaptive vaccination strategy over the seasonal influenza
Figure 2. Age-specific hospitalization and case fatality rates
given hospitalization estimated from cumulative morbidity
and mortality data from the National Surveillance System
stratified by four broad age groups at two time points into the
S-OIV outbreak in Mexico. The Ministry of Health issued an
epidemiologic alert on April 16 and 17 and selective reporting of
severe pneumonia cases ceased on April 29. Case fatality rate is
estimated as the proportion of deaths among hospitalized pneumonia
cases.
doi:10.1371/journal.pone.0008164.g002
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Figure 3. Age-specific incidence curves of clinical cases, hospitalizations and deaths in the context of the 2009 S-OIV outbreak in
Mexico. We considered a baseline situation with R0 = 1.6 where no vaccine is used (top panel), a seasonal vaccination strategy (middle panel) where
priority groups for vaccination are young children and seniors, as for seasonal influenza, and an adaptive vaccination strategy (bottom panel) where
vaccine is allocated according to data on age-specific rates of mortality. The vaccination coverage is 20% and vaccination is initiated 25 days after the
epidemic onset when an epidemiologic alert was issued in Mexico.
doi:10.1371/journal.pone.0008164.g003
Table 2. Comparison of predicted rates (per 100,000 people) of hospitalizations and death in the context of the 2009 S-OIV
outbreak in Mexico, for various concurrent vaccination strategies.
Baseline (no
interventions) Seasonal vaccination strategy Adaptive vaccination strategy
Vaccination
coverage 5%
Vaccination
coverage 20%
Vaccination
coverage 5%
Vaccination
coverage 20%
Hospitalizations 12202 11357 (7%) 9395 (23%) 11085 (9%) 7714 (37%)
Deaths 1665 1593 (4%) 1419 (15%) 1490 (11%) 954 (43%)
We considered a baseline situation where no vaccine is used; a seasonal vaccination strategy where priority groups for vaccination are young children and seniors, as for
seasonal influenza; and an adaptive vaccination strategy where vaccine is allocated according to data on age-specific rates of mortality and hospitalization with a
baseline R0 = 1.6 [26] and vaccination coverage is 5 or 20%. Vaccination is initiated 25 days after the epidemic onset when an epidemiologic alert was issued in Mexico.
doi:10.1371/journal.pone.0008164.t002
Influenza Vaccination
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vaccination strategy were significantly greater than those obtained
for the moderate pandemic scenario. For the severe pandemic
scenario, the adaptive strategy yielded reductions of 36% and 37%
in the overall number of hospitalizations and deaths, respectively,
if vaccination started on day 10 of the outbreak and reached 20%
of the population. The additional benefits of the adaptive
vaccination strategy ranged from 1–55% added reduction in
hospitalization and 1–29% reduction in deaths, compared with the
seasonal influenza vaccination strategy. The largest added benefits
of the adaptive strategy were found at higher vaccination
coverage, lower R values, and earlier start of vaccination
campaigns, in line with results for the moderate pandemic
scenario. For the severe pandemic scenario illustrating the
epidemiology of the 1918 pandemic, the age group prioritized
by the adaptive strategy was adults aged 20–39 y followed by
40–59 year-olds.
Discussion
With today’s technologies, little to no vaccines would be
immediately available for most of the world at the time of
emergence of a novel pandemic virus to contain a potential
‘‘herald’’ wave, as was observed during the summer of 1918 in the
US and Europe [4,7,39]. A similar situation occurred with the first
wave of the S-OIV pandemic in Mexico and elsewhere in spring
2009. Previous models [16,17,18] predicted that containment of
pandemic influenza could not succeed unless multiple medical and
non-medical interventions were layered and applied early, a low to
zero probability scenario given the rapidity of events in influenza
transmission and global spread. Given the time line of vaccine
production and delivery for pandemic viruses, a realistic use of
vaccination would be its concurrent delivery during an ongoing
pandemic, in particular during a second or third wave.
In this study, an age-structured model of influenza transmission,
hospitalization and death, was used to explore the effectiveness of
various age-targeted vaccination strategies in pandemic scenarios
reminiscent of the epidemiology of the novel S-OIV A/H1N1
outbreak in Mexico in the spring of 2009 and past pandemics. The
model integrates age variation in vaccine efficacy and probability
of severe disease outcomes, as well as direct and indirect benefits of
vaccination. The adaptive vaccination strategy relying on data on
hospitalization and deaths reported as early as 25 days into the
 
 
 
 
 
 
 
 
Figure 4. Comparison of concurrent vaccination strategies for novel S-OIV pandemic influenza scenarios. Strategies include adaptive
vaccination targeted at high-risk groups identified from real-time hospitalization and death data, and seasonal vaccination strategy targeted at young
children and seniors. Plots illustrate the additional reduction (%, see color bar) in hospitalizations (top) and deaths (bottom) averted by the adaptive
vaccination allocation strategy, compared to the seasonal influenza strategy, as a function of R (using plausible ranges, R = 1.4–1.8) and vaccination
coverage (5–20%). In the left panels, vaccination is initiated 25 days into the outbreak, on April-17-2009, when the epidemiologic alert was issued. In
the right panels, vaccination is initiated 37 days into the outbreak, on Apr-29-2009, when selective reporting of severe pneumonia cases ceased. The
adaptive strategy allocates vaccine given the age-specific patterns of hospitalization and mortality available on those dates (Figure 2).
doi:10.1371/journal.pone.0008164.g004
Influenza Vaccination
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outbreak was the most effective to reduce deaths and hospitaliza-
tions when vaccine resources were scarce and substantially
outperformed the seasonal influenza allocation strategy for a
range of parameter values. In particular, the adaptive strategy
would provide additional reductions of up to 22% and 35% in
hospitalizations and deaths compared to the ‘seasonal’ vaccination
strategy targeting traditional high-risk groups, at 20% vaccine
coverage. This assumes that the population between 20 and 59
years would be preferentially targeted, in contrast to seniors and
young children who are traditionally prioritized. Although a
variety of alternative vaccine allocation schemes are possible, here
we focused on the seasonal strategy as a reference baseline
strategy, since it is the most widely used to control seasonal
influenza globally.
Similar benefits were obtained for other pandemic scenarios
illustrating the epidemiology of the 1918, 1957 and 1968
pandemics, and a wider range of R0 values. The adaptive strategy
produced 2–20% additional reductions in deaths and hospitaliza-
tions when applied to the 1918 pandemic scenario, relative to the
seasonal allocation strategy, for the range of parameters
considered. It is interesting that both the 1918 and 2009
pandemics have particularly young age distribution of severe
cases: while the 1918 pandemic caused mortality mostly in persons
below the age of 45 [9,39], the current 2009 H1N1 pandemic
affects mostly those under 55 [25]. Because of the pronounced shift
in pandemic deaths towards younger age groups in those
pandemics, the benefits of the adaptive strategy are enhanced as
compared to the seasonal strategy.
Direct and indirect effects of vaccination are incorporated in
this study, including differential rates of transmission within and
between age-groups and age-variation in vaccine efficacy. While
school-age children amplify influenza transmission locally, adults
are likely responsible for inter-regional spread [40], including in
the current H1N1 pandemic [41]. We note that interruption of
transmission was not achieved in any of the vaccination scenarios
considered here, including those targeting high-transmitter groups.
This is likely because we explored low vaccination coverage, never
exceeding 20%, and vaccination was assumed to start well into the
outbreak in most scenarios.
An adaptive vaccination strategy requires rapid ascertainment
of cases, hospitalizations and/or deaths, to help identify high risk
age groups for prioritization of vaccine and other pharmaceutical
interventions, including antivirals and antibiotics [42,43]. In the
2009 swine flu outbreak, the optimal strategy could be identified
with confidence as early as day 25 of the Mexican outbreak, given
knowledge on the age pattern of severe cases and local availability
of real-time data. Had a vaccine been available in quantities
sufficient to cover 20% of the population, this would have given
enough time to initiate a vaccination campaign and avert an
additional 22% of hospitalizations and 35% of deaths compared to
a seasonal vaccination strategy if vaccination started 25 days after
the epidemic onset. Alternatively, if local epidemiological data are
not available in real time, data from other countries experiencing
earlier or simultaneous outbreaks could be used to calibrate the
adaptive strategy. Such a strategy might be particularly useful in
the case of returning outbreaks of S-OIV in the fall, in Mexico and
elsewhere.
Virological subtyping of a novel pandemic virus can provide an
early clue to target vaccination efforts. Each of the previous
pandemics had unique age-mortality patterns [9] that could be
explained by previous exposure during childhood of a subset of the
population to the novel circulating viral sub-type [1,32,10]. While
the elderly are normally at most risk for severe outcomes during
seasonal influenza, warranting the targeting of vaccination for
direct protection to that group, they may have residual protection
during pandemics. By contrast, younger groups generally respond
better to vaccine [34,33] and provide a greater reduction of
transmission. Given residual protection in seniors in early
pandemic waves, younger age groups become a clear priority
group for pandemic vaccine allocation. In the current 2009
pandemic, assuming an annual attack rate of approximately 10–
20% for inter-pandemic influenza, those who were born between
1919 and around 1957 would have been first exposed to H1N1
during their childhood and may enjoy protection against S-OIV
infection and death, as observed in the early wave of S-OIV in
Mexico [25].
Several studies have assessed the effects of potential vaccination
strategies against pandemic influenza [24,44,45,46,47,48,49] in
terms of reducing morbidity and mortality based on priority age
groups, transmissibility, timing of vaccination efforts [24], and
number of years of life lost [45]. A recent study [24] has evaluated
the influenza vaccine allocation problem considering a vaccination
coverage of 35% at the pandemic onset or near the pandemic peak
when the population is stratified by age and low and high risks.
Results suggest that vaccine should be allocated to individuals with
high-risk complications whenever the vaccine becomes available
late in the pandemic (close to the peak) while targeting high
transmitter groups (children) is more effective when the vaccine is
available close to the start of the pandemic. Most studies of
influenza vaccination strategies to date have assumed a given
epidemiological profile based on past influenza epidemics and
pandemics but have not necessarily considered novel profiles that
could arise in future pandemics. Given high levels of uncertainty as
to the epidemiology of the next outbreak of S-OIV or other novel
influenza virus, unfortunately, no single strategy can fit all
scenarios. Our adaptive strategy is flexible enough to accommo-
date a range of possible scenarios illustrating our experience with
past pandemics, and potentially new ones.
We note that other interventions strategies have been proposed
to mitigate the burden of pandemic influenza. Social distancing
and facemasks have been suggested as mitigation strategies, but
their efficacy against pandemics remains debated. Strategies
involving antiviral treatments are helpful to mitigate disease
burden, but resources are limited and effectiveness assumes speedy
delivery and susceptibility of circulating viruses. Any of these
interventions could be used in combination with the adaptive
vaccine allocation strategy proposed here.
Mexico began vaccinating against seasonal influenza in 2004,
and annual campaigns target children 6 to 23 months old, adults
over 65 years, and those with chronic conditions [50]. In the past,
Mexico has relied on other countries for influenza vaccine
production, which in the setting of a pandemic is likely to be
available in limited supplies. Although a preparedness and
response plan against pandemic influenza for Mexico had been
drafted with the objective of optimizing resources and conducting
a timely response [51,52], it lacks guidance on how to define
priority groups in the scenario of a limited vaccine supply. Our
study shows that even limited vaccine supplies, if used optimally,
can have an impact on mitigating disease burden in a middle-
income country like Mexico.
There are many limitations to policy models with respect to choice
of parameter estimates and the incorporation of bio-medical,
environmental, operational, political, economic features. No one
model can claim to incorporate all assumptions and features given the
limited data on the epidemiology of novel pandemic viruses and
paucity of data on contact rates, especially in Mexico. This model
illustrates a prioritization scheme based on age-groups but does not
further discriminate other sub-groups such as those persons with other
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medical conditions including pregnancy. Models do not necessarily
provide answers but help articulate the questions, assumptions and
numerous uncertainties in rapidly evolving circumstances as a tool to
formulate rational policy based on the best available evidence.
Pandemics evolve rapidly relative to capabilities to enact policies;
therefore, pre-formulated adaptive strategies can readily take into
account new data. Knowledge of the specific sub-type circulating and
real-time information on age-specific rates of severe outcomes are
crucial to help policy makers infer who may be at most risk, and tailor
intervention strategies accordingly. These adaptive pandemic strategies
could be readily adopted by other countries.
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Figure S6 Age-specific incidence curves of clinical cases,
hospitalizations and deaths for a baseline scenario with the
1918-like pandemic profile without vaccination with R_0 = 1.8
(top panel) and the impact of a seasonal influenza vaccination
strategy with R_0 = 1.8, start of vaccination at day 10 of epidemic
onset, average per-capita time to vaccination of 5 days and a
vaccination coverage of 20% (bottom panel).
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Figure S7 Age-specific incidence curves of clinical cases,
hospitalizations and deaths for a baseline scenario under the
moderate pandemic scenario of hospitalization and mortality
without vaccination with R_0 = 1.8 (top panel) and the impact of a
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vaccination at day 10 of epidemic onset, average per-capita time to
vaccination of 5 days and a vaccination coverage of 20% (bottom
panel).
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EPS)
Figure S8 Comparison of concurrent vaccination strategies for
1918-like and typical pandemic influenza scenarios. Strategies
include adaptive vaccination targeted at high-risk groups identified
from hospitalization and death data, and seasonal vaccination
strategy targeted at young children and seniors. Reduction (%) in
hospitalizations (top) and deaths (bottom) averted by the adaptive
vaccination allocation strategy compared to the seasonal influenza
strategy as a function of R and vaccination coverage (%) under the
moderate pandemic scenario (left) and the characteristic 1918
influenza pandemic profile (right) of hospitalization and mortality
when vaccination starts 30 days after the epidemic onset.
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